A61K38/04

Polypeptides including a beta-tricalcium phosphate-binding sequence and uses thereof
11192923 · 2021-12-07 · ·

Provided herein are beta-TCP binding sequences and chimeric polypeptides that include one or more beta-TCP binding sequences and a mammalian growth factor, compositions comprising any of these chimeric polypeptides (and optionally, beta-TCP), and methods of promoting bone or cartilage formulation, methods of replacing and/or repairing bone or cartilage, and methods of treating a bone fraction or bone loss that include administration of any of these compositions.

Anti-inflammatory peptides and composition comprising the same

A peptide with anti-inflammatory activity, wherein the peptide comprises SEQ ID NO: 1, the peptide has above 80% homology of amino acid sequence with above-mentioned sequence, or the peptide is the fragment of the above-mentioned peptides is described. An anti-inflammatory composition comprising the above mentioned peptides is described. According to the present invention, a peptide comprising a sequence of SEQ ID NO: 1 has outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptide of this invention can be used as anti-inflammatory pharmaceutical composition or as cosmetic composition, in turn, treating and preventing a variety of different types of inflammatory diseases.

ANTIMICROBIAL TAILORED CHITOSAN

The invention relates to a bio-conjugate comprising a chitosan derivative coupled to antimicrobial peptides (AMPs) for use in the treatment or prevention of microbial infections such as wound healing. The invention also provides a nanoparticles formulation or a gel/hydrogel formulation or a lyophilized foam formulation comprising the bio-conjugate of the invention.

Plant defense signaling peptides and applications thereof
11363822 · 2022-06-21 · ·

The present invention is related to a novel plant defense signaling peptide and applications thereof.

Antiviral immunotropic agent for the treatment of acute respiratory viral infections

The proposed methods of treatment pertain to medicine, in particular pharmacology, and concerns the application of a nasal medicinal composition containing hexapeptide tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine or its pharmaceutically acceptable salt for the treatment of acute respiratory viral infections (ARVIs), in particular those caused by the influenza virus.

Ligand controling interaction between gags with their effector molecules and use thereof

The invention relates to new compounds that mimic Glycosaminoglycans and are able to control interaction between Glycosaminoglycans with their effector molecules. The compounds of the invention are peptides and are able to prevent or reduce the binding of at least one effector molecule with at least one glycosaminoglycan. The compounds according to the invention can be used as drug, in particular for the stimulation of the neurogenesis and more generally to treat nervous system related pathologies.

Ligand controling interaction between gags with their effector molecules and use thereof

The invention relates to new compounds that mimic Glycosaminoglycans and are able to control interaction between Glycosaminoglycans with their effector molecules. The compounds of the invention are peptides and are able to prevent or reduce the binding of at least one effector molecule with at least one glycosaminoglycan. The compounds according to the invention can be used as drug, in particular for the stimulation of the neurogenesis and more generally to treat nervous system related pathologies.

Therapeutic Compositions Directed To Host Mirna For The Treatment Of Sars-Cov-2 (Covid-19) Infection

The inventive technology generally relates to systems, methods, and compositions for the treatment of viral infections, as well as novel use of antisense technology to rationally design antiviral compositions that can be applied to clinical cases and human infections. In one preferred aspect, the inventive technology includes methods, and compositions to treat COVID-19 in humans through the targeted inhibition of host-derived miRNAs.

Therapeutic Compositions Directed To Host Mirna For The Treatment Of Sars-Cov-2 (Covid-19) Infection

The inventive technology generally relates to systems, methods, and compositions for the treatment of viral infections, as well as novel use of antisense technology to rationally design antiviral compositions that can be applied to clinical cases and human infections. In one preferred aspect, the inventive technology includes methods, and compositions to treat COVID-19 in humans through the targeted inhibition of host-derived miRNAs.

Mixtures of sabadilla alkaloids and <i>Bacillus thuringiensis </i>and uses thereof

The present invention is directed to pesticidal mixtures comprising sabadilla alkaloids and Bacillus thuringiensis and methods of controlling pests including insects and mites by application of pesticidal mixtures comprising sabadilla alkaloids and Bacillus thuringiensis.